EU/3/19/2153

About

On 24 April 2019, orphan designation (EU/3/19/2153) was granted by the European Commission to Neuroplast B.V., Netherlands, for autologous human bone marrow-derived haematopoietic and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes (also known as Neurocell) for the treatment of spinal cord injury.

Key facts

Active substance
Autologous human bone marrow-derived haematopoietic and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes
Disease / condition
Treatment of spinal cord injury
Date of first decision
24/04/2019
Outcome
Positive
EU designation number
EU/3/19/2153

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Neuroplast B.V.
Oxfordlaan 55
6229 EV Maastricht
Limburg
Netherlands
Tel: +31 6 1589 7008
E-mail: h.demunter@neuroplast.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating